Report of the working groups on breast MRI: Report of the high-risk screening group

Breast Journal

Volumn 10, Issue SUPPL. 2, 2004, Pages

  Lehman, Constance D ^a   Schnall, Mitchel D ^b   Kuhl, Christiane K ^c   Harms, Steven E ^d  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

High risk; Screening

Indexed keywords

BREAST CANCER; CANCER SCREENING; CONFERENCE PAPER; GENE MUTATION; GENETIC PREDISPOSITION; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; MASS SCREENING; NUCLEAR MAGNETIC RESONANCE IMAGING;

BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MASS SCREENING; RISK; SENSITIVITY AND SPECIFICITY;

EID: 4644244017     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2004.21434-3.x     Document Type: Conference Paper

References (18)

1. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
2. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73:643-51.
3. Benichou J, Gail MH, Mulvihill JJ. Graphs to estimate an individualized risk of breast cancer. J Clin Oncol 1996;14:103-10.
4. Li CI, Malone KE, Weiss NS, Daling JR. Use of tamoxifen for primary breast cancer in relation to risk of contralateral breast cancer. J Natl Cancer Inst 2001;93:1008-13.
5. Kollias J, Ellis IO, Elston CW, Blamey RW. Prognostic significance of synchronous and metachronous bilateral breast cancer. World J Surg 2001;25:1117-24.
6. Fowble B, Hanlon A, Freedman G, Nicolaou N, Anderson P. Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys 2001;51:679-90.
7. Yahalom J, Petrek JA, Biddinger PW, et al. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol 1992;10:1674-81.
8. Burke W, Daly M, Garber JE, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. 2. BRCA1 and BRCA2. JAMA 1997;277:997-1003.
9. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
10. Kuhl CK, Schmutzler RK, Leutner CC, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000;215:267-79.
11. Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001;19:3524-31.
12. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, de Koning HJ, Oudkerk M. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000;63:53-60.
13. Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of pre-operative contrast-enhanced MR imaging on the therapeutic approach. Radiology 1999;213:881-88.
14. Lanetz PJ, Edmister WB, Weisskoff RM, et al. Occult contralateral breast cancer detected by breast MR [abstract]. Radiology 1998;2(P);467.
15. Woo IJ, Orel SG, Schnall MD, et al. MR imaging of the contralateral breast in patients with newly diagnosed breast cancer [abstract]. Radiol Suppl 2000;217:526.
16. Linver MN, Osusch JR, Brenner RJ, Smith RA. The mammography audit: a primer for the Mammography Quality Standards Act (MQSA). AJR Am J Roentgenol 1995;165:19-25.
17. Sickles EA. Quality assurance: how to audit your own mammography practice. Radiol Clin N Am 1992;30:265-75.
18. Quality Mammography Standards: Final Rule of the Department of Health and Human Services and Food and Drug Administration, 21 CFT 16 and 900, 1997.